[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351736-105":59,"doc-detail-351736-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","recent-advances-in-pancreatic-cancer-and-biliary-tract-cancers-biology-biomarkers-and-evolving-systemic-therapy","Recent Advances in Pancreatic Cancer and Biliary Tract Cancers - Biology, Biomarkers, and Evolving Systemic Therapy","","Pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTCs) remain highly lethal gastrointestinal malignancies because of late presentation, marked molecular heterogeneity, and limited durable benefit from conventional systemic therapy. This narrative review summarizes recent advances, highlighting practice-informing clinical trials, biomarker-driven treatment strategies, and translational insights into tumor biology and resistance. It describes progress in perioperative care, molecular testing, targeted and combination approaches, and expanding precision options in BTC, including actionable alterations and emerging circulating tumor DNA applications.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/recent-advances-in-pancreatic-cancer-and-biliary-tract-cancers-biology-biomarkers-and-evolving-systemic-therapy/351736/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/recent-advances-in-pancreatic-cancer-and-biliary-tract-cancers-biology-biomarkers-and-evolving-systemic-therapy/351736.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are PDAC and biliary tract cancers difficult to treat?","Question",{"text":113,"@type":114},"They are highly lethal due to late presentation, strong molecular heterogeneity, and limited durable benefit from standard systemic therapy, along with frequent recurrence even after potentially curative treatment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What role do biomarkers and molecular profiling play in BTC management?",{"text":118,"@type":114},"Comprehensive molecular profiling helps identify actionable alterations in a substantial proportion of BTCs, supporting precision oncology, clinical trial matching, and therapy selection based on tumor drivers.",{"name":120,"@type":111,"acceptedAnswer":121},"How are circulating tumor DNA (ctDNA) and immunotherapy discussed across PDAC and BTCs?",{"text":122,"@type":114},"ctDNA is presented as an emerging tool for prognosis, minimal residual disease assessment, response monitoring, and early resistance detection. Immunotherapy shows a clearer role in selected BTC populations, while PDAC benefit remains largely limited to rare biomarker-defined subsets.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351736,1790192991,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Review  \nRecent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy  \nEhab Takrori 1, Mahmoud Abdulmajid 2, Deepthi Devagudi 3, Ramsha Sohail 4, Zaynah Sadiq 5, Chris Berneau 4, Andrew Shenouda 4, Rakesh Adelli 6, Supriya Peshin 4, * and Sakshi Singal 7, *  \nAcademic Editor: Giorgio Malpeli  \nReceived: 16 March 2026  \nRevised: 5 May 2026  \nAccepted: 14 May 2026  \nPublished: 15 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia; [etakrori@gmail.com](etakrori@gmail.com)  \n2 School of Medicine, University of Jordan, Amman 11942, Jordan; [abdelmajeedmahmood@gmail.com](abdelmajeedmahmood@gmail.com)  \n3 Department of Hospital Medicine, Adventist Health, Hanford, CA 93230, USA; [devagudideepthi@gmail.com](devagudideepthi@gmail.com)  \n4 Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA; [ramshas376@gmail.com](ramshas376@gmail.com) (R.S.); [cberneau1@gmail.com](cberneau1@gmail.com) (C.B.)  \n5 Washington Health, Fremont, CA 94538, USA; [zaynahsadiq@gmail.com](zaynahsadiq@gmail.com)  \n6 Center for Applied Research and Evaluation in Women’s Health, Department of Health Services Management & Policy, East Tennessee State University, Johnson City, TN 37614, USA; [adelli@etsu.edu](adelli@etsu.edu)  \n[7](7 Department of Hematology & Oncology)[ Department of Hematology & Oncology](7 Department of Hematology & Oncology), [East Tennessee State University](East Tennessee State University), [Johnson City](Johnson City), [TN 37604](TN 37604), [USA](USA)[ ](USA)* Correspondence: [supriyapeshin720@gmail.com](supriyapeshin720@gmail.com) (S.P.); [singal@etsu.edu](singal@etsu.edu) (S.S.)  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTCs) remain highly lethal gastrointestinal malignancies because of late presentation, marked molecular heterogeneity, and limited durable benefit from conventional systemic therapy. This narrative review summarizes recent advances in both diseases, focusing on practice-informing clinical trials, biomarker-driven treatment strategies, and translational insights into tumor biology and resistance. In PDAC, progress includes refinement of perioperative management, broader germline and somatic testing, recognition of DNA damage repair-deficient subsets, and development of KRAS-directed therapies and rational combination strategies. In BTCs, especially intrahepatic cholangiocarcinoma, comprehensive molecular profiling has expanded precision oncology through actionable alterations such as FGFR2 rearrangements, IDH1 mutations, HER2 amplification/overexpression, BRAF V600E, NTRK fusions, and MSI-high/dMMR status. Immunotherapy has a clearer role in selected BTC populations, whereas in PDAC benefit remains largely restricted to rare biomarker-defined subsets. Across both diseases, circulating tumor DNA is emerging as a promising tool for prognostication, minimal residual disease assessment, response monitoring, and early resistance detection. Contemporary care increasingly depends on early molecular profiling, individualized treatment sequencing, and integration of targeted therapies, biomarker-guided immunotherapy, and clinical trials.  \nKeywords: pancreatic ductal adenocarcinoma; biliary tract cancers; cholangiocarcinoma; gallbladder cancer; molecular profiling; targeted therapy; immunotherapy; antibody–drug conjugates; tumor microenvironment; precision oncology; treatment sequencing; biomarkers  \n1. Introduction  \nPancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTCs), including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder carcinoma, remain among the most clinically challenging gastrointestinal malignancies, largely because most patients pres","cbCaibtiBfu9CIjM","https://ap.wps.com/l/cbCaibtiBfu9CIjM","pdf",2658593,33,"English","# Abstract\n# Keywords\n# Introduction\n## Pancreatic ductal adenocarcinoma (PDAC) challenges and progress\n## Biliary tract cancers (BTCs) transition to precision oncology\n## Importance of multidisciplinary molecular testing\n## Practice-changing clinical trial directions","[{\"question\":\"Why are PDAC and biliary tract cancers difficult to treat?\",\"answer\":\"They are highly lethal due to late presentation, strong molecular heterogeneity, and limited durable benefit from standard systemic therapy, along with frequent recurrence even after potentially curative treatment.\"},{\"question\":\"What role do biomarkers and molecular profiling play in BTC management?\",\"answer\":\"Comprehensive molecular profiling helps identify actionable alterations in a substantial proportion of BTCs, supporting precision oncology, clinical trial matching, and therapy selection based on tumor drivers.\"},{\"question\":\"How are circulating tumor DNA (ctDNA) and immunotherapy discussed across PDAC and BTCs?\",\"answer\":\"ctDNA is presented as an emerging tool for prognosis, minimal residual disease assessment, response monitoring, and early resistance detection. Immunotherapy shows a clearer role in selected BTC populations, while PDAC benefit remains largely limited to rare biomarker-defined subsets.\"}]","Recent Advances in Pancreatic Cancer and Biliary Tract Cancers - Biology, Biomarkers, and Evolving Systemic Therapy | PDF",1790095580,83,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d14c6faee6437d0be766b8f8c4c2868.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10cfd27f25d597b70b6bd97657f3b795.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e6ceca149d9bc4531f4e1b74d9eb4ec.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d979f127808a423b525dd9c18f9d226d.webp",980,1385]